Dose numbers for oral formulations are not comparable to injectable ones

On the subject in the title: Dose numbers for oral formulations are not comparable to injectable ones Working notes rather than a conclusion.

Putting the numbers in the first post, because a question about a compound without them turns into a question about somebody's impression of it.

oral semaglutide, monoisotopic mass near 4113.6 Da, 14 weeks of my own notes, and 5 lots from 2 suppliers with a purity figure on each. That is the whole basis of what follows.

What I want checked is the reasoning I have built on top of it, not the figures themselves.

Oral semaglutide's bioavailability is low and variable, which is why the dose numbers are an order of magnitude different from the injectable. That is a formulation consequence and not a difference in potency.

Someone will know this better than I do and I hope they say so.

Adding the measurement that post #2 says would settle it.

Oral bioavailability is variable between people. Some people absorb well; others absorb poorly. That inter-individual variation is larger than with injectables and is one reason the trial data for oral formulations receives different treatment.

The opening post describes the usual case. This is about the unusual one.

Anyone comparing published oral and injectable efficacy should check whether the comparison is within one trial or across two. Across two, the populations differ and the comparison is weak.

That is my reading. Someone else read the same page differently and was reasonable.

Building on post #2 rather than restating it.

Taking the oral product with more water than instructed reduces absorption rather than helping it. That is counter-intuitive and it is one of the few dosing instructions in this field with a clear pharmacokinetic basis.

Trial adherence in an oral trial with strict administration requirements is genuinely worse than trial-published data often suggests. That is why the exposure variability in oral formulations is mentioned repeatedly in the discussions here.

Anyone with a larger sample, please post it.

PIONEER 6 was a cardiovascular safety trial for oral semaglutide, not an efficacy trial. Non-inferiority for safety was demonstrated. The point estimates favoured the drug but the trial was not designed to establish benefit.

Grateful for the specificity. Vague answers to this question are what sent me looking.

Taking post #6 at face value and following it one step further.

On variability: the between-person spread in exposure for oral semaglutide is wide enough that two people on the same dose can have quite different plasma concentrations. That is inherent to the absorption route.

Post #9 and I disagree about the size of the effect, not about the direction.

PIONEER programme is phase 3 for oral semaglutide. The trials cover multiple indications and durations. Reading them requires attention to which trial is which because they are not all the same question.

The practical argument for an oral is adherence, and the published adherence data is less flattering than the argument. Daily dosing with fasting requirements is not obviously easier than a weekly injection.

The SOUL trial: cardiovascular outcomes trial for oral semaglutide in people with type 2 diabetes and cardiovascular disease or chronic kidney disease. It demonstrates that benefit appears to be a property of the molecule and exposure, not specific to the route.

Not the answer, but possibly the question that gets there.

The thirty-minute wait before eating is not conservatism. Food in the stomach materially reduces absorption of the oral product, and the instruction exists because the pharmacokinetic studies measured how much.

It is one reading of the data and not the only reasonable one.

Taking post #11 at face value and following it one step further.

Tablet integrity matters more than people expect for a formulation that depends on an absorption enhancer released at a particular place. Splitting or crushing is not a dose adjustment; it is a different product.

That is a description of practice, not a recommendation of it.